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Daptomycin is a cyclic lipopeptide antibiotic that is increasingly relied upon for the treatment of methicillin-resistant *Staphylococcus aureus* (MRSA) infections ([@B1]). Daptomycin-nonsusceptible strains (defined by a MIC \> 1.0 µg/mL) have recently been described, however, the genetic mechanism behind the emergence of these strains is not completely understood ([@B2], [@B3]). We, and others, have performed whole-genome sequencing of daptomycin-exposed strains, identifying point mutations in numerous genes including those important for phospholipid metabolism (most notably the lysl-phosphatidylglycerol synthase, encoded by *mprF*), as well as the two-component regulatory system, *walKR,* and RNA polymerase subunits *rpoB* and *rpoC* ([@B2], [@B4][@B5][@B6]). In order to further understand the development of daptomycin resistance in *S. aureus*, we prepared the draft genome sequence of a daptomycin-susceptible strain, APS210 (daptomycin MIC 0.5 µg/mL), isolated from a patient with bacteremia and compared it to its daptomycin nonsusceptible derivative, APS211 (daptomycin MIC 4.0 µg/mL), that emerged after daptomycin treatment and therapeutic failure.

Genomic DNA from APS210 and APS211 was prepared using a QIAGEN blood and tissue kit per the manufacturer's instructions and sequenced using Illumina MiSeq (250-bp paired-end reads) generating 5,255,342 and 4,468,075 reads, respectively. Draft genomes were assembled *de novo* using CLC workbench (v6.0.2) with \>1,000× coverage and each genome was annotated using the NCBI Prokaryotic Genomes Annotation Pipeline. The genome sequence of APS210 comprised 83 contigs (\>500 bp in length, *N*~50~ = 74,505 bp) with a combined length of 2,906,880 bp, G+C content of 32.7%, and 2,859 predicted protein-coding regions. The sequence of APS211 comprised 72 contigs (\>500 bp in length, *N*~50~ = 73,502 bp) with a combined length of 2,905,661 bp and G+C content of 32.7%. Both strains were sequence type (ST) 45 and staphylococcal cassette chromosome *mec* (SCC*mec*) type V ([@B7]). Comparison of the two genomes revealed four single nucleotide polymorphisms (SNPs) including a mutation that led to the previously described MprF amino acid substitution, S337L ([@B2], [@B8]). Two of the SNPs were predicted to be synonymous within hypothetical proteins (a predicted phage protein and a protein with similarity to *N*-acyl-[l]{.smallcaps}-amino acid amidohydrolase) and the final SNP was predicted to be intergenic. Defining the precise molecular mechanisms behind MprF-mediated daptomycin-nonsusceptibility in *S. aureus* is ongoing in our laboratory.

Nucleotide sequence accession numbers. {#s1}
--------------------------------------

The whole-genome shotgun sequences of APS210 and APS211 have been deposited in DDBJ/EMBL/GenBank under the accession numbers [JXUD00000000](JXUD00000000) and [JXUV00000000](JXUV00000000), respectively.
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